1 se duodenal gastrinomas are often minute and
multicentric.
2 e common in unicentric (262/278; 94.2%) than
multicentric (
49/126; 38.9%) disease (chi(2) 146.8; P <
3 ore 10 months of age and developed immature,
multicentric aggressive T-cell leukemia/lymphomas.
4 bjects in brain regions showing PrP-positive
multicentric amyloid deposits.
5 scant foci of spongiform change, and diffuse
multicentric amyloid plaques, selectively immunoreactive
6 Retrospective
multicentric analysis of patients treated for SU.
7 le to converge toward their conclusions in a
multicentric and multiethnic setting.
8 A
multicentric and retrospective study of 31 patients (22
9 r levels of HHV-8 DNA in those patients with
multicentric and visceral involvement than in those pati
10 t differences were found in the frequency of
multicentric and/or multifocal disease (luminal A, 27.3%
11 reports from 441 patients were reviewed for
multicentric and/or multifocal disease, lymph node invol
12 ple (when multifocal, it was formerly called
multicentric BAC).
13 the pathologic/radiologic concept of diffuse/
multicentric BAC.
14 Fifty-nine patients with multifocal or
multicentric breast lesions proven by either fine-needle
15 Multicentric cancer detected only at MR imaging was inva
16 An unsuspected additional
multicentric cancer seen only at MR imaging is likely cl
17 kely to be invasive than MR imaging-detected
multicentric cancers (88% vs 76%, P = .023).
18 MR imaging-detected
multicentric cancers and index cancers differed in histo
19 n the index quadrant despite the presence of
multicentric cancers elsewhere in the breast.
20 5%) (95% CI: 15, 36) had MR imaging-detected
multicentric cancers larger than 1 cm.
21 35) patients had larger MR imaging-detected
multicentric cancers than the known index lesion, and 18
22 atients (95% CI: 2, 13), MR imaging-detected
multicentric cancers were potentially more biologically
23 a minority of additional MR imaging-detected
multicentric cancers.
24 Multicentric carcinoid tumors occurred in 15 patients (1
25 liver metastases between solitary (18%) and
multicentric carcinoids (20%).
26 Multicentric carpal-tarsal osteolysis; multicentric oste
27 ization of monocyte-derived macrophages from
multicentric carpotarsal osteolysis (Online Mendelian In
28 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman desease.
29 HIV-associated
multicentric Castleman disease (HIV MCD) is a rare lymph
30 Successful treatment of HIV-associated
multicentric Castleman disease (HIV+MCD) with rituximab-
31 HIV-associated
multicentric Castleman disease (HIV-MCD) is a rare lymph
32 HIV-associated
multicentric Castleman disease (HIV-MCD) presents with s
33 Kaposi sarcoma (KS) herpesvirus-associated
multicentric Castleman disease (KSHV-MCD) is a lymphopro
34 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (KSHV-MCD) is characteriz
35 been rarely reported as a heralding sign of
multicentric Castleman disease (MCD) and other lymphopro
36 is the causative agent of two B cell tumors,
multicentric Castleman disease (MCD) and primary effusio
37 (KSHV) led to recognition of KSHV-associated
multicentric Castleman disease (MCD) as a distinct lymph
38 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (MCD) is a lymphoprolifer
39 Multicentric Castleman disease (MCD) is a lymphoprolifer
40 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (MCD) is a lymphoprolifer
41 Kaposi sarcoma herpesvirus (KSHV)-associated
multicentric Castleman disease (MCD) is a polyclonal B-c
42 HIV-associated
multicentric Castleman disease (MCD) is associated with
43 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman disease (MCD) patients.
44 e causative agent of Kaposi sarcoma (KS) and
multicentric Castleman disease (MCD), a life-threatening
45 with primary effusion lymphoma (PEL) and/or
multicentric Castleman disease (MCD), and in 18 (60.0%)
46 disorders: primary effusion lymphoma (PEL),
multicentric Castleman disease (MCD), and MCD-associated
47 igens were investigated in patients with KS,
multicentric Castleman disease (MCD), and primary effusi
48 mary effusion lymphoma, and plasma cell-type
multicentric Castleman disease (MCD).
49 , namely primary effusion lymphoma (PEL) and
multicentric Castleman disease (MCD).
50 nd 4 from Central/South America), and 2 with
multicentric Castleman disease (MCD).
51 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman disease (MCD).
52 d with monotypic (IgMlambda) plasmablasts in
multicentric Castleman disease (MCD).
53 quences have been described in some cases of
multicentric Castleman disease (MCD).
54 sting as primary effusion lymphoma (PEL) and
multicentric Castleman disease (MCD).
55 ary effusion lymphoma (PEL), and a subset of
multicentric Castleman disease (MCD).
56 Multicentric Castleman disease and hemophagocytic syndro
57 Localized and
multicentric Castleman disease are different clinical di
58 (KS) to either primary effusion lymphoma or
multicentric Castleman disease B-cell malignancies, and
59 lasias such as primary effusion lymphoma and
multicentric Castleman disease in AIDS patients.
60 ia and persistent lymphadenopathy resembling
multicentric Castleman disease in rhesus macaques (RMs)
61 HIV-associated plasmablastic
multicentric Castleman disease is an increasingly freque
62 ANA in a subset of cells in lytically active
multicentric Castleman disease lesions.
63 tment with rituximab in posttrans-plantation
multicentric Castleman disease patients and non-neoplast
64 d entities: Kaposi sarcoma, HHV-8-associated
multicentric Castleman disease with microlymphomas and a
65 sarcoma (KS), primary effusion lymphoma, and
multicentric Castleman disease.
66 ma (KS), primary effusion lymphoma (PEL) and
multicentric Castleman disease.
67 expression of TbetaRII in Kaposi sarcoma and
multicentric Castleman disease.
68 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman disease.
69 ith KS, primary effusion lymphoma (PEL), and
multicentric Castleman disease.
70 initial presentation as having localized or
multicentric Castleman disease.
71 induced hyperplasia to monoclonal neoplasia:
multicentric Castleman's disease (CD), Kaposi's sarcoma
72 readily detected in KSHV-positive cells from
multicentric Castleman's disease (MCD) and Kaposi's sarc
73 Multicentric Castleman's disease (MCD) describes a heter
74 effusion lymphoma (PEL) cell lines, PEL and
multicentric Castleman's disease (MCD) tumors, Kaposi's
75 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD), all of which are
76 alignancies including Kaposi's sarcoma (KS),
multicentric Castleman's disease (MCD), and primary effu
77 us casually linked to Kaposi's sarcoma (KS),
multicentric Castleman's disease (MCD), and primary effu
78 ic agent of primary effusion lymphoma (PEL),
multicentric Castleman's disease (MCD), and the inflamma
79 man's disease (UCD) or the dominant focus in
multicentric Castleman's disease (MCD), nature of the su
80 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD), three diseases t
81 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD).
82 ancies: primary effusion lymphomas (PEL) and
multicentric Castleman's disease (MCD).
83 ry effusion lymphomas (PEL), and a subset of
multicentric Castleman's disease (MCD).
84 cavity-based primary effusion lymphomas, and
multicentric Castleman's disease (MCD).
85 d B-cell lymphomas (BCBLs) and in lesions of
multicentric Castleman's disease (MCD).
86 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD).
87 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease (MCD).
88 sorders, primary effusion lymphoma (PEL) and
multicentric Castleman's disease (MCD).
89 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease (MCD).
90 resemble KSHV-associated diseases including
multicentric Castleman's disease and non-Hodgkin's lymph
91 to two B cell lymphoproliferative disorders,
multicentric Castleman's disease and primary effusion ly
92 ive care alone for patients with symptomatic
multicentric Castleman's disease and well tolerated with
93 Multicentric Castleman's disease describes a group of po
94 tified 626 (33%) patients with HHV8-negative
multicentric Castleman's disease from 1923 cases of mult
95 24 (19%) of 128 patients with idiopathic
multicentric Castleman's disease had a diagnosis of a se
96 Human herpesvirus 8 (HHV8) causes
multicentric Castleman's disease in immunosuppressed pat
97 First-line treatments for idiopathic
multicentric Castleman's disease included corticosteroid
98 Clinical features of idiopathic
multicentric Castleman's disease included multicentric l
99 Multicentric Castleman's disease is a rare lymphoprolife
100 The cause of HHV8-negative
multicentric Castleman's disease is idiopathic; such cas
101 128 patients with idiopathic
multicentric Castleman's disease met all inclusion crite
102 of centralised information about idiopathic
multicentric Castleman's disease represents a major chal
103 e cells infected with human herpesvirus-8 in
multicentric Castleman's disease support lytic replicati
104 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease through autocrine or pa
105 K1 was readily detected in
multicentric Castleman's disease tissues, whereas it was
106 egated data for 127 patients with idiopathic
multicentric Castleman's disease were presented from cli
107 be the etiologic agent of Kaposi's sarcoma,
multicentric Castleman's disease, and AIDS-associated pr
108 KSHV causes primary effusion lymphomas,
multicentric Castleman's disease, and Kaposi's sarcoma.
109 (KSHV) is the etiologic agent for KS tumors,
multicentric Castleman's disease, and primary effusion l
110 us (KSHV) is found in Kaposi's sarcoma (KS),
multicentric Castleman's disease, and primary effusion l
111 with the development of Kaposi's sarcoma and
multicentric Castleman's disease, as well as a rare form
112 ssociated with primary effusion lymphoma and
multicentric Castleman's disease, as well as its namesak
113 tures, treatment, and outcomes of idiopathic
multicentric Castleman's disease, which accounts for at
114 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
115 ses, including primary effusion lymphoma and
multicentric Castleman's disease.
116 include primary effusion lymphoma (PEL) and
multicentric Castleman's disease.
117 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
118 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
119 athogenesis of primary effusion lymphoma and
multicentric Castleman's disease.
120 ies, including primary effusion lymphoma and
multicentric Castleman's disease.
121 i's sarcoma, primary effusion lymphomas, and
multicentric Castleman's disease.
122 sarcoma (KS), primary effusion lymphoma, and
multicentric Castleman's disease.
123 primary effusion lymphoma, and some forms of
multicentric Castleman's disease.
124 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
125 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
126 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
127 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
128 primary effusion lymphoma, and plasmablastic
multicentric Castleman's disease.
129 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
130 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
131 as well as of primary effusion lymphoma and
multicentric Castleman's disease.
132 gnancies, KS, primary effusion lymphoma, and
multicentric Castleman's disease.
133 usion lymphoma and the plasmablastic form of
multicentric Castleman's disease.
134 imary effusion lymphoma and in some cases of
multicentric Castleman's disease.
135 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
136 as well as in primary effusion lymphoma and
multicentric Castleman's disease.
137 tve disorders, primary effusion lymphoma and
multicentric Castleman's disease.
138 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
139 of KS, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
140 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
141 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
142 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
143 sarcoma (KS), primary effusion lymphoma, and
multicentric Castleman's disease.
144 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
145 primary effusion lymphoma and some cases of
multicentric Castleman's disease.
146 related non-Hodgkin's lymphomas (NHL) and in
multicentric Castleman's disease.
147 ch accounts for at least 33% of all cases of
multicentric Castleman's disease.
148 in body cavity-based lymphomas (BCBL) and in
multicentric Castleman's disease.
149 ody cavity-based lymphomas, and AIDS-related
multicentric Castleman's disease.
150 ted lymphomas, and from a high proportion of
multicentric Castleman's disease.
151 ntric Castleman's disease from 1923 cases of
multicentric Castleman's disease.
152 posi sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease.
153 , treatments for, and outcomes of idiopathic
multicentric Castleman's disease.
154 idiopathic; such cases are called idiopathic
multicentric Castleman's disease.
155 a (KS), primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
156 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
157 interleukin 6-in HIV-negative patients with
multicentric Castleman's disease.
158 rus-8-seronegative patients with symptomatic
multicentric Castleman's disease.
159 arcoma, primary effusion lymphoma (PEL), and
multicentric Castleman's disease.
160 si's sarcoma, primary effusion lymphoma, and
multicentric Castleman's disease; in all of these diseas
161 s been associated with both malignancies and
multicentric Castleman's disease; the latter is a rare a
162 Multicentric chromosomes are often found in tumor cells
163 ut not inactive, centromeres of prometaphase
multicentric chromosomes using antibodies to the cytopla
164 romotes formation of ectopic centromeres and
multicentric chromosomes, which causes chromosome misseg
165 Brachytherapy should be included in
multicentric clinical trials in young children.
166 tory cohort was independently validated in a
multicentric cohort of 194 AML patients.
167 more likely to help detect multifocal and/or
multicentric disease and lymph node involvement in lumin
168 ry, but complete remissions in patients with
multicentric disease have been achieved only with chemot
169 The 8 patients with
multicentric disease were further subdivided according t
170 In
multicentric disease, outcomes are comparable between de
171 1.2% vs 34.4%; chi(2) 28.6; P < 0.0001) than
multicentric disease.
172 combination chemotherapy, or prednisone for
multicentric disease.
173 ndependently predictive of multifocal and/or
multicentric disease.
174 ntly compared with R-CHOP(21) induction in a
multicentric European protocol.
175 of the first recognized autosomal-recessive,
multicentric forms of the disorder.
176 causative agent of Kaposi's sarcoma (KS), a
multicentric growth factor-dependent tumor common in AID
177 ining age, gender, centricity (unicentric vs
multicentric),
histopathologic type (hyaline vascular [H
178 We then undertook a
multicentric international phase III study to compare th
179 Overall, the size of MR imaging-detected
multicentric invasive cancers (median, 0.6 cm; range, 0.
180 Six patients had
multicentric involvement (4-15 lesions), primarily of th
181 heavy smokers consecutively recruited by the
Multicentric Italian Lung Detection, or MILD, trial.
182 e hypothesis that the spindle cells in these
multicentric lesions originate from a single clone of pr
183 ffer between the index lesion and additional
multicentric lesions seen only at MR imaging.
184 in breast cancer patients with multifocal or
multicentric lesions, contrary to the common belief of s
185 , selection for an X-linked allele in clonal
multicentric lesions.
186 ic multicentric Castleman's disease included
multicentric lymphadenopathy (128/128), anaemia (79/91),
187 V-945 LTR and SU into FeLV-A/61E resulted in
multicentric lymphoma of non-T-cell origin.
188 a T-cell origin to an as yet uncharacterized
multicentric lymphoma that did not contain T cells.
189 us macaque (Macaca mulatta) that developed a
multicentric lymphoproliferative disorder (LPD).
190 It is almost always
multicentric (
MCD) and linked to human herpesvirus 8 (HH
191 whether patients with clinical multifocal or
multicentric (
MFMC) breast cancer determined by mammogra
192 In contrast,
multicentric monophasic IMDS patients with putative evid
193 e progression of Parkinson's disease and its
multicentric neurodegeneration provides the best hope of
194 A
multicentric,
noninferiority, randomized controlled tria
195 We designed a
multicentric,
observational study to test if Procalciton
196 mixed) and two clinical types (localized and
multicentric)
of Castleman disease have been described.
197 and modular data handling platform to enable
multicentric off-site image reading for incidental findi
198 Multicentric or multifocal breast cancer is considered a
199 ive predictive values of SLN localization in
multicentric or multifocal breast lesions.
200 atients mammographically suspected of having
multicentric or multifocal disease.
201 I study in which patients with symptomatic,
multicentric or unresectable, unicentric CD received sil
202 We discover a
multicentric organization with fields that vary dramatic
203 The
multicentric osteolyses are notable for interphalangeal
204 mal recessive osteolysis/arthritis syndrome,
multicentric osteolysis with arthritis (MOA) (MIM #60515
205 tly described an autosomal recessive form of
multicentric osteolysis with carpal and tarsal resorptio
206 Multicentric carpal-tarsal osteolysis;
multicentric osteolysis, nodulosis, and arthropathy; and
207 In this open-label, randomized,
multicentric,
parallel group clinical trial, 240 patient
208 rials 1 single method easily applicable in a
multicentric PET review must be selected and kept all al
209 In a prospective and
multicentric phase III clinical study, the value of (18)
210 77 developed hyperplastic LPD resembling the
multicentric plasma cell variant of Castleman's disease,
211 meters of renal function and morphology in a
multicentric population-based cohort.
212 We find that each
multicentric primary tumor harbors distinct oncogenic al
213 sk factors have been identified to date, but
multicentric prospective studies on anastomotic leak aft
214 We performed a
multicentric prospective trial including all ABO-incompa
215 Method: We conducted a
multicentric,
quasiexperimental, interrupted time series
216 nagement of stress urinary incontinence with
multicentric randomized controlled trials.
217 However, further
multicentric randomized studies will confirm the exact r
218 (retrospective
multicentric registry and Mainz Intracoronary Database.
219 In this cohort study, a
multicentric registry of patients with BCP (from Cancer
220 ry, radiographic, and histologic findings in
multicentric reticulohistiocytosis are reviewed.
221 We describe a patient with
multicentric reticulohistiocytosis in whom complete remi
222 s of complete or near-complete remissions of
multicentric reticulohistiocytosis reported in the Engli
223 In addition, all published cases of
multicentric reticulohistiocytosis which included report
224 report describes the case of a patient with
multicentric reticulohistiocytosis.
225 Design, Setting, and Participants:
Multicentric retrospective cohort study of images from 1
226 This retrospective
multicentric study included 213 patients who underwent L
227 This retrospective
multicentric study included 53 patients with a history o
228 This
multicentric study was conducted between 2009 and 2014 i
229 This large
multicentric survey shows that surgery is in current pra
230 We developed a
multicentric Swiss protocol for ABO-incompatible kidney
231 122 patients with PTCL was collected from a
multicentric T-cell lymphoma consortium (TENOMIC).
232 Purpose Kaposi's sarcoma (KS) is a
multicentric tumor caused by Kaposi's sarcoma-associated
233 aindications to breast preservation included
multicentric tumors, diffuse indeterminate microcalcific
234 Women with operable breast cancer and
multicentric tumors, with ductal carcinoma in situ (DCIS
235 Women with operable breast cancer and
multicentric tumors, with ductal carcinoma in situ, who
236 This prospective,
multicentric,
uncontrolled pilot study enrolled patients
237 chronic therapy-refractory HE in a European
multicentric working group and to identify patients who